SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation P243R

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations

An open-label, non-randomized, single arm study to assess the safety, tolerability, and pharmacokinetics of FP-1039 given by weekly intravenous (IV) administrations in advanced endometrial cancer patients with FGFR2-specific mutations. FP-1039 will be dosed weekly starting at a dose of up to 16 mg/kg.

NCT01244438 Endometrial Cancers With FGFR2 Mutations Drug: FP-1039
MeSH: Endometrial Neoplasms
HPO: Endometrial carcinoma

Evidence of histologically or cytologically proven metastatic or locally advanced unresectable endometrial cancer bearing either the S252W or the P243R FGFR2 mutation. --- S252W --- --- P243R ---

Primary Outcomes

Description: To assess the response rate of advanced endometrial cancer patients bearing FGFR-specific mutations

Measure: Response rate

Time: up to 1 year

Description: To assess 6-month progression free survival of advanced endometrial cancer patients bearing FGFR-specific mutations

Measure: Progression-free survival

Time: 6 months

Secondary Outcomes

Description: To evaluate the safety and tolerability of FP-1039 in subjects with advanced endometrial cancer

Measure: Safety and tolerability

Time: up to 1 year

Description: To determine pharmacokinetics (PK) plasma concentration at specified times

Measure: Pharmacokinetics of Plasma

Time: up to 1 year


HPO Nodes


Endometrial carcinoma
Genes 23
PMS2 SDHB CDH1 GREM1 POLD1 NTHL1 MSH6 BMPR1A POLE SDHC KLLN MSH2 MSH6 SDHD SEC23B MSH6 PTEN MLH1 POLD1 PIK3CA MLH3 AKT1 MSH3